Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort
Authors:
- The Japan Study Group of Prostate Cancer (J-CaP)T(The Japan Study Group of Prostate Cancer (J-CaP)
- Teruo InamotoTITeruo Inamoto
- Haruhito AzumaHAHaruhito Azuma
- 28 March 2014
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 140 (7) , 1197-1204
Abstract
Primary androgen deprivation therapy (PADT) had been used extensively in Japan than in the USA and European countries regardless of the disease risk or patient’s age. To illustrate the consequence of PADT from daily clinical practice, we evaluated the relationship among age, disease risk, and survival of patients with prostate cancer treated by PADT in largest Asian cohort. The 19,246 men subjected to PADT enrolled in the Japan Study Group of Prostate Cancer were enrolled for the present analysis. Patients were divided into four groups based on age at diagnosis: age 75. Risk was stratified according to the Japan Cancer of the Prostate Risk Assessment (J-CAPRA). Multivariate competing risks regression analysis was performed for OS and PFS. There was downward stage migration over age. Among men aged >75 years, 34.1 % had nodal or distant metastatic disease. In contrast, 56.0 % of patients aged p < 0.0001 by Pearson’s chi-square test). The same as OS, the PFS rate increased with age until after the age of 75. Men aged 71–75 had better survival rates even after adjustments for treatment modality alone, or for treatment modality plus disease risk. Age cohorts do affect orientation toward favorable disease course after PADT with men aged 71–75 being benefiting more from PADT than other age groups.Keywords
This publication has 21 references indexed in Scilit:
- Neoadjuvant Hormonal Therapy Use and the Risk of Death in Men with Prostate Cancer Treated with Brachytherapy Who Have No or at Least a Single Risk Factor for Coronary Artery DiseaseEuropean Urology, 2014
- External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy seriesUrologic Oncology: Seminars and Original Investigations, 2012
- Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its ManagementJapanese Journal of Clinical Oncology, 2012
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation TherapyJournal of Clinical Oncology, 2009
- Radical prostatectomy in men aged ≥70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogramBJU International, 2008
- Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaPJapanese Journal of Clinical Oncology, 2007
- Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995–2004Cancer, 2007
- The Case for Androgen Deprivation as Primary Therapy for Early Stage Disease: Results From J-CaP and CaPSURE™Journal of Urology, 2006
- Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen FailureJournal of Clinical Oncology, 2005